Key result
First-line right internal jugular leadless pacemaker implantation yields ~98% procedural success with low 30-day complications.
Why the study?
Does a first-line right internal jugular vein approach achieve high feasibility, procedural success, and 30-day safety for leadless pacemaker implantation in patients with a guideline-directed indication?
Cohort (n=272)
Yes
Does a first-line right internal jugular vein approach achieve high feasibility, procedural success, and 30-day safety for leadless pacemaker implantation in patients with a guideline-directed indication?
This prospective multicenter registry demonstrates that a first-line right internal jugular vein approach for leadless pacemaker implantation is highly feasible (97.8% success) and safe, with a low 30-day major complication rate of 2.2%.
Answers are grounded in this paper and cite their sources.
RIJV leadless pacemaker implantation achieved 98% success with low complications; leaves open its role as first-line versus femoral access pending randomized data.
BACKGROUND: Leadless pacemakers (LPs) are usually implanted through the femoral vein. The right internal jugular vein (RIJV) approach has emerged as an alternative, but evidence remains limited to retrospective single-centre series. OBJECTIVE: To evaluate the feasibility, procedural success, and 30-day safety of a first-line RIJV approach for LP implantation. METHODS: The VAMPIRE study (NCT06455566) is a prospective, investigator-initiated, multicenter registry enrolling consecutive patients with a guideline-directed LP indication across 15 tertiary centres in France (May 2024-May 2026). The primary endpoint was major procedure- or system-related complications within 30 days. RESULTS: Of 294 screened patients, 272 (92.5%) underwent a first-line RIJV approach. The cohort was elderly (median age 79 [73-85] years), predominantly male (63.6%), with high comorbidity burden including atrial fibrillation in 51.5%, chronic kidney disease in 34.9%, and cancer in 22.4%. High-degree atrioventricular block was the primary indication in 84.9%; 65.8% of procedures were performed urgently. Successful LP implantation was achieved in 266 of 272 patients (97.8%; 95% CI 95.3-99.2%), with septal deployment in 94.3%. Median procedure time was 30 [25-40] minutes and median fluoroscopy time 2.5 [1.1-7.0] minutes. Major complications occurred in 6 of 272 patients (2.2%; 95% CI 0.8-4.7%; p<0.001). CONCLUSION: In this prospective multicenter registry of a first-line RIJV approach for LP implantation, feasibility and procedural success were high, and 30-day major complications rate low. These results support the RIJV route as a safe and broadly applicable access strategy for LP implantation. However, dedicated studies are needed to compare safety versus the femoral approach.
No takes yet. Share an insight, caveat, or question.
Ollitrault et al. (2026) conducted a cohort in Guideline-directed leadless pacemaker indication (predominantly high-degree atrioventricular block) (n=272). Leadless pacemaker implantation via a first-line right internal jugular vein (RIJV) approach was evaluated on Major procedure- or system-related complications within 30 days (95% CI 0.8-4.7%, p=<0.001). First-line right internal jugular vein leadless pacemaker implantation achieved 97.8% procedural success with a 2.2% 30-day major complication rate.
Synapse has enriched 10 related papers. Consider them for comparative context: